The CDF Healthcare Practitioner Directory is a free listing of physicians, dieticians, mental health professionals and allied health providers in all 50 states with experience treating people who have a gluten-related condition. The directory also allows you to search for specific practice types, insurance plans accepted, and hospital affiliations. The goal is to help people find physicians and other practitioners who know something about celiac disease. The foundation believes this will help get more people diagnosed (currently, less than 20% of those with celiac disease know they have the condition). It's not clear how much the directory will help people who live outside of major cities -- a couple of quick searches involving fairly rural areas turned up a handful of gastroenterologists within 50 or 100 miles in each case, but these doctors' "knowledge of celiac disease" was listed as "unknown." However, I'm guessing the current listings are only a start, and the CDF will continually update the directory over time, making it an even more valuable resource. I frequently receive emails from people asking me to help them find a doctor. Now, I'll have somewhere to send them. Keep up with the latest in the celiac disease/gluten sensitivity world -- sign up for my newsletter , connect with me on Facebook and Google+ , or follow me on Twitter - @AboutGlutenFree .
BioLineRx Enters Clinic with Novel Treatment for Celiac Disease
Results are expected in mid-2014. The Phase 1/2 study is a two-part (single and repeated), double-blind, placebo-controlled, dose escalation study of BL-7010 in up to 32 patients. The primary objective of the study is to assess the safety of single and repeated ascending doses of BL-7010 in well-controlled celiac patients. Secondary objectives include an assessment of the systemic exposure, if any, of BL-7010 in the study patients. "The commencement of BL-7010's Phase 1/2 study in a world-leading celiac treatment center is an important milestone in the development of one of our most promising projects," said Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx. "Based on our pre-clinical results to date, we are very enthusiastic about this unique product, which is also generating a lot of excitement from both the scientific and medical communities. Celiac disease is an autoimmune condition that causes damage to the small intestine, and is associated with other autoimmune disorders, as well as with osteoporosis, infertility, neurological conditions and even cancer. Although 1% of the world's population suffers from this disease, there are currently no approved celiac therapeutics, and the only treatment available today is a gluten-free diet that is exceptionally difficult and costly to maintain. In addition, there are an extremely small number of clinical-stage projects under development worldwide for celiac disease, which we see as a significant opportunity for our product." Dr.
Misdiagnosis, noncompliance often culprits in refractory celiac disease
Type 2 is the most pernicious, with nearly half of patients dying within 5 years of diagnosis, either from malignant or infectious complications, according to Dr. Murray. "Type 2 refractory disease is not a trivial disease," he said. Although most adults with celiac disease dont heal, many are asymptomatic; however, this does not mean a patients risk of mortality from the disease has improved. Patients are also at greater risk for malignant complications. ( Am. J. Gastroenterol. 2010;105:1412-20 [doi:10.1038/ajg.2010.10] ). "We really dont know what we should do about those asymptomatic patients," said Dr. Murray.
find out here http://www.familypracticenews.com/specialty-focus/child-adolescent-medicine/single-article-page/misdiagnosis-noncompliance-often-culprits-in-refractory-celiac-disease/4fbed47fba0858810f8c92176f474276.html?tx_ttnews%5BsViewPointer%5D=1